<DOC>
	<DOCNO>NCT00017264</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase I trial study effectiveness atrasentan treat patient progressive recurrent malignant glioma .</brief_summary>
	<brief_title>Atrasentan Treating Patients With Progressive Recurrent Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose atrasentan patient progressive recurrent malignant glioma . - Describe pharmacokinetics drug patient . - Assess preliminary evidence therapeutic activity drug patient . OUTLINE : This dose-escalation , multicenter study . Patients receive oral atrasentan daily . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 2-10 patient receive escalate dos atrasentan maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 1 patient experience dose-limiting toxicity . Patients follow every 2 month . PROJECTED ACCRUAL : Approximately 35 patient accrue study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Atrasentan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant glioma Anaplastic astrocytoma Anaplastic oligodendroglioma Glioblastoma multiforme Progressive recurrent prior radiotherapy without chemotherapy Prior lowgrade glioma progress highgrade therapy allow Measurable disease MRI CT scan PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL Transaminases great 4 time upper limit normal Hepatitis A , B , C negative Renal : Creatinine great 1.7 mg/dL Cardiovascular : No New York Heart Association class II , III , IV cardiac disease Other : HIV negative Mini mental score least 15 No malignancy within past 5 year except curatively treat carcinoma situ basal cell skin cancer No serious concurrent infection No concurrent medical illness would preclude study entry No alcoholism drug addiction within past 6 month Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent anticancer immunotherapy Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy ( 6 week nitrosoureas ) recover No 1 prior chemotherapy regimen No prior concurrent polifeprosan 20 carmustine implant ( Gliadel wafer ) No prior atrasentan No concurrent anticancer chemotherapy Endocrine therapy : No concurrent anticancer hormonal therapy Radiotherapy : See Disease Characteristics At least 3 month since prior radiotherapy recover No concurrent anticancer radiotherapy Surgery : No concurrent anticancer surgery Other : Recovered prior therapy No 1 prior treatment regimen No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2004</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>